2019 Volume 21 Issue 4 Published: 28 August 2019
  

  • Select all
    |
  • Cai Haodong
    Abstract ( ) PDF ( )
    Anticoagulant therapy is an effective method to prevent or treat vascular thromboembolism, but there are also many safety problems. The most common adverse reaction of anticoagulants is bleeding. Intracranial hemorrhage and gastrointestinal hemorrhage, which sometimes even threaten their lives, may occur in severe cases. Attention should be paid to thrombocytopenia induced by heparin anticoagulants and adverse reactions such as liver injury, rash and skin injury, and kidney injury associated with new oral anticoagulants. The safety problems of anticoagulants are related not only to the drugs themselves, but also to the different indications, opportunities, and drug variety due to their application in various clinical departments; the anticoagulants are mostly applied to elderly outpatients, which makes their supervision more difficult. Medical staffs in various clinical departments should pay attention to the safety management of anticoagulants, strictly follow the relevant guidelines, try to accumulate more experience in clinical application, and ensure the medication safety of patients.
  • Zhao Zinan, Zhu Yuanchao, Liang Liang, Chen Di, Zhang Yatong
    Abstract ( ) PDF ( )
    ObjectiveTo systematically evaluate the risk of major bleeding and major adverse cardiac events(MACE) in patients with acute coronary syndrome(ACS) after combined use of novel oral anticoagulants (NOAC) and antiplatelet therapy.MethodsRandomized controlled trials (RCTs) about NOAC treatment for ACS patients with basic antiplatelet therapy in related databases (up to July 2018) were searched. The outcome indicators included major bleeding events (safety indicators) and MACE (effectiveness indicators). Quality of methodology was evaluated using bias risk assessment tool of Cochrane collaboration networks. Meta-analysis was performed using RevMan 5.3 software.ResultsA total of 6 RCTs were entered, including comparative studies of single antiplatelet therapy (SAPT) or dual antiplatelet therapy (DAPT) combined with NOAC and combined with placebo or warfarin, involving 20 070 patients. Drugs used in the trial group included apixaban, rivaroxaban, and dabigatran etexilate. The quality evaluation showed that 4 of the 6 RCTs were with low risks of bias and 2 with high risks of bias. The meta-analysis showed that the risk of clinical major bleeding events in patients in the SAPT+NOAC group was significantly higher than that in the SAPT+placebo group [3.14% (44/1 402) vs. 1.07% (19/1 770), RR=3.47, 95%CI: 2.01-5.97, P<0.001]. The incidence of clinical major bleeding events in patients in the DAPT+NOAC group was significantly higher than that in the DAPT+placebo group [5.72% (387/6 761) vs. 2.79% (251/8 984), RR=2.59, 95%CI: 1.73-3.86, P<0.001], but significantly lower than that in the DAPT+warfarin group[17.22% (422/2 450) vs. 25.68% (627/2 442), RR=0.68, 95%CI: 0.56-0.82, P<0.001]. The risk of MACE in patients in the SAPT+NOAC group was significantly lower than that in the SAPT+placebo group [8.61% (121/1 405) vs. 12.20% (217/1 779), OR=0.69, 95%CI: 0.55-0.88, P=0.003]; there were no significant differences in the risks of MACE between patients in the DAPT+NOAC group and the DAPT+placebo group or DAPT+warfarin group (P>0.05 for both).ConclusionsCombination of anticoagulants and SAPT or DAPT in ACS patients may all increase the risk of clinical major bleeding, but combination of SAPT and NOAC may reduce the risk of MACE, and should be used after weighing. For patients who must be treated with triple antithrombotic therapy, DAPT combined with NOAC can be chosen and warfarin should be avoided.
  • Li Zhengrong, Wang Juan, Wu Fangfang, Che Fengyuan, Li Hongyan, Shi Zengcheng, Ou Zhihong
    Abstract ( ) PDF ( )
    ObjectiveTo explore the predictive value of INR in early stage  of warfarin therapy (early INR) for anticoagulation intensity after 7 days of treatment.MethodsThe medical records of patients hospitalized in the Department of Cardiology, Linyi People′s Hospital, Shandong University from January 2012 to May 2015 were collected, who received warfarin anticoagulation therapy and underwent INR tests in the morning after 3 or 7 days of medication. The early INR meant INR after 3 days of warfarin treatment. According to INR after 7 days of warfarin treatment, the patients were divided into 2 groups, anticoagulation up to standard (INR 2.0-3.0) group and over-anticoagulation (INR>3.0) group. The best critical value of early INR for predicting INR after 7 days of warfarin treatment was obtained by plotting ROC curve. The risk of over-anticoagulation after 7 days of warfarin treatment was compared in patients with early INR ≥ critical value and<critical value. Univariate analysis was used to compare the clinical characteristics in the 2 groups. The indexes with P<0.100 were used as covariate and multivariate logistic regression analysis was performed. The odds ratio (OR) and its 95% confidence interval (CI) was calculated and independent risk factors of INR>3.0 after warfarin treatment were screened.ResultsA total of 75 patients with atrial fibrillation were enrolled in the study, including 38 males and 37 females, aged (64±9), 42 patients in the anticoagulation up to standard group and 33 patients in the over-anticoagulation group. There were significant differences in body weight, INR after 3 days of medication, and the number of patients with hypoproteinemia between the 2 groups (all P<0.05), but no significant differences in other indicators (all P>0.05). The results of ROC curve showed that the best critical value of anticoagulation intensity predicted by early INR was 1.67, the area under the curve was 0.915[95%CI: 0.828-0.967], and the sensitivity and specificity were 0.95 and 0.82, respectively. The risk of over-anticoagulation in patients with 7 days of warfarin treatment in the group with early INR ≥1.67 was significantly higher than that in the group with early INR <1.67 [90.0%(27/30) vs. 13.3%(6/45), χ2=39.883, OR=58.50, 95%CI: 13.45-254.48, P<0.001]. Multivariate logistic regression analysis showed that early INR≥1.67 was an independent risk factor for over-anticoagulation after 7 days of treatment (OR=48.719, 95%CI: 10.891-217.940, P<0.001).ConclusionsThe early INR can predict anticoagulation intensity after 7 days of treatment. Early INR ≥1.67 is an independent risk factor for over-anticoagulation after 7 days of warfarin treatment.
  • Tang Lian, Zhou Mengyue, Zhuang Zhiwei, Lu Jian, Shen Yi, Xu Xiaowen, Zhou Qin, Xue Sudong, Yu Yanxia
    Abstract ( ) PDF ( )
    ObjectiveTo explore the risk factors for coagulation events after argatroban anticoagulation in patients receiving renal replacement therapy (RRT).MethodsThe medical records of patients at high risk of bleeding, who received RRT combined with argatroban anticoagulation in ICU of the Affiliated Suzhou Hospital of Nanjing Medical University (Suzhou Municipal Hospital) from January 2015 to March 2017, were collected and analyzed retrospectively.ResultsA total of 65 patients were enrolled, including 36 males and 29 females, aged (75.4±19.7) years. A total of 372 RRT cycles were performed, including 72 cycles in the coagulation events group because of coagulation events occurence and the remaining 300 cycles in the non-coagulation events group. Univariate logistic regression analysis showed that platelet count (OR=0.990, 95%CI: 0.978-1.001, P=0.084) and serum calcium level at the time of finishing RRT (OR=5.722, 95%CI: 2.183-14.999, P<0.001), first dose (OR=0.712, 95%CI: 0.498-1.017, P=0.062), initial micropump dosage (OR=0.614, 95%CI: 0.368-1.026, P=0.063), and adjusted micropump dosage(OR=0.587, 95%CI: 0.353-0.977, P=0.040) of argatroban, and transmembrane pressure at the time of finishing RRT (OR=1.010, 95%CI: 1.006-1.014, P<0.001) were associated with coagulation events. Multivariate logistic regression analysis showed that serum calcium level and transmembrane pressure at the time of finishing RRT were independent risk factors of coagulation events (OR=4.007, 95%CI: 1.107-15.793, P=0.047; OR=1.012, 95%CI: 1.005-1.018, P=0.008). The ROC curve showed that the risk of coagulation events increased when serum calcium level at the time of finishing RRT was more than 2.6 mmol/L or transmembrane pressure at the time of finishing RRT was more than 206 mmHg.ConclusionSerum calcium level and transmembrane pressure at the time of finishing RRT are independent risk factors of coagulation events after argatroban anticoagulation during RRT.
  • Wang Chunhui, Li Jing, Wu Wei, Li Wensi, Li Xiaoyu, Lyu Qianzhou
    Abstract ( ) PDF ( )
    ObjectiveTo evaluate the cardiac safety of trastuzumab-containing regimens in patients with HER2-positive tumors.MethodsThe clinical data of adult patients with HER2-positive breast cancer, gastric cancer or gastroesophageal junction adenocarcinoma, with normal electrocardiogram and echocardiography before treatments, and treated with trastuzumab-containing regimens in Zhongshan Hospital Affiliated to Fudan University from January 2016 to February 2018 were collected through the hospital information system and cardiac adverse events after trastuzumab-containing regimens were retrospectively analyzed., The patients were divided into 4 groups according to the application history of antineoplastic drugs: group A (neither anthracyclines nor fluoropyrimidines application history), group B (only anthracyclines application history), group C (only fluoropyrimidines application history), and group D (both anthracyclines and fluoropyrimidines application history). The occurrences of cardiac adverse events in the 4 groups were compared.ResultsA total of 90 patients were enrolled, including 34 males and 56 females, aged (60±12) years. Of them, 43 patients (47.8%) were with breast cancer, 46 (51.1%) were with gastric cancer, and 1 (1.1%) was with gastroesophageal junction adenocarcinoma. Group A, B, C, and D comprised 11, 20, 52, and 7 patients, respectively. Of the 90 patients, 65 patients developed 96 cases of adverse cardiac events. The incidence of adverse cardiac events was 72.2%. The severity of cardiac adverse events was grade 1 in 91 cases and grade 2 in 5 cases. The adverse events with higher incidence were arrhythmia (36.7%, 33/90), abnormal cardiac structure (22.2%, 20/90), valvular reflux (22.2%, 20/90), and increased pulmonary arterial systolic pressure (10.0%, 9/90). There was no significant difference in the incidence of cardiac adverse events after trastuzumab treatment in patients with different antineoplastic drug application history among the 4 groups (all P>0.05). Except for 2 patients with grade 2 sinus tachycardia whose heart rate returned to normal after treatment with beta-blocker, the other 63 patients did not need medical intervention.ConclusionThe incidence of cardiac adverse events of trastuzumab treatment in patients with HER2-positive tumors was higher, but the severity of most of them were grade 1, which rarely cause serious cardiac functional or structural damage.
  • Liu Yi, Jing Qing, Bian Yuan, Yan Junfeng
    Abstract ( ) PDF ( )
    ObjectiveTo evaluate the effectiveness of self-established 33 triggers in detecting drug adverse events (ADE) in children and explore child-individual factors possibly associated with ADE.MethodsTwo hundred medical records of inpatient in Sichuan Provincial People′s Hospital, who discharged from January 1, 2017 to September 30, 2017, were sampled using the sampling method recommended by the global trigger tool white paper of U.S. Institute for Healthcare Improvement. The medical records were detected using the self-established 33 ADE triggers. If there were positive triggers, whether the children developed ADE, the classification, grading, and causal judgement of ADE, types of common drugs causing ADE in children, and the association between the individual factors in children and ADE were further analyzed.ResultsIn the 200 medical records, 200 children were involved, including 128 males and 72 females, aged from 38 minutes after birth to 18 years with the average age of 6 years. The time of hospital stay was 2 to 43 days with the average time of 10 days. Of the 200 medical records, 128 had at least 1 positive trigger, and the positive trigger rate was 64.0% (95%CI: 57%-71%). Of the 33 triggers, 29 were triggered  a total of 394 times, and 98 ADE were detected, involving 41 children. Thus the detectable rate of the triggers was 20.5%(41/200), and the positive predictive value (PPV) of the triggers in detecting ADE was 24.9% (95%CI: 20.1%-28.0%). Ninety eight ADE could be classified into 12 categories, and ADE such as abnormal white blood cell count (21.4%, 21 times), skin lesions (11.2%, 11 times), and abnormal platelet count (10.2%, 10 times) were more common. The proportion of ADE that were grading as grade 1, grade 2, and grade 3 were 39.8% (39 times), 56.1% (55 times), and 4.1% (4 times), respectively. In the causality determination, 4 (4.1%), 73 (74.5%), 19 (19.4%), 1(1.0%), and 1 (1.0%) ADE were determined as certain, probable, possible, conditional, and unassessable. Ninety eight ADE involved 18 classes (including 52 kinds) of drugs, and the frequency of drug occurrence ranged from 1 to 16 times, with a total of 143 times. Anti-tumor drugs (44.1%,63 times) appeared most frequently, and followed by antibacterial agents (23.8%,34 times). Logistic regression analysis showed that hospital stay and diagnosis of leukemia were positively correlated with the likelihood of ADE occurrence.ConclusionsThe self-established 33 triggers could effectively monitor ADE in children, despite that further improvements were necessary. The individual factors in children that might be associated with ADE were more hospitalization days and suffering from leukemia.
  • Lu Yun
    Abstract ( ) PDF ( )
    Clinical benefit of anticoagulants in the treatment of thrombotic events, stroke or myocardial infarction is obvious, but their clinical risk should be weighed in each clinical setting. The improper use of anticoagulants may not only increase risk of readmission, lengthen hospitalization due to bleeding or thrombotic events, but also increase the risk of mortality. The unique pharmacokinetics and pharmacodynamics of each anticoagulant in a specific patient with different pathophysiology increases the challenge for medication safety management. Medication error is also one of the important reasons for the risk of anticoagulants in clinic. In December 2018, Joint Commission of the United States made safe use of oral anticoagulants among national patient safety goals. The standard for the safety use of anticoagulants in the certification requirement were increased from six to eight. The American Institute for Safe Medication Practices has also listed anticoagulants as high-alert medications. It calls for clinical pharmacists and multidisciplinary experts to create protocols to safe guard anticoagulant usage to improve patient safety.
  • Yao Wenxin, Liu Wei, Liu Zhijun
    Abstract ( ) PDF ( )
    The traditional concept was that combination of 2 or more kinds of drugs with higher plasma-protein binding degree might increase the free concentration of 1 or more of the drugs due to their competition for plasma-protein binding, which eventually might enhance the efficacy and toxicity of the drugs. But in the clinical practice, the combination of drugs with higher plasma usually did not develop so many serious drug interactions protein binding degree. It was demonstrated from the following 4 aspects in this article that combination of drugs with higher plasma-protein binding degree was less likely to result in clinically significant interactions due to competition for plasma protein binding: (1) the amount of proteins that could bind to drugs in plasma was greater than that of the drug molecules; (2) apparent drug volume of distribution (Vd); (3) plasma clearance rate of drug; (4) area under plasma concentration-time curve. It was necessary to re-recognize the inherent concept above-mentioned.
  • un Lirui, Zhang Hongmei, Guo Qiushi, Tian Xu, Sun Zhihui
    Abstract ( ) PDF ( )
    A 35-year-old male patient received an IV infusion of flurbiprofen axetil 100 mg, which was diluted in 100 ml of 0.9% sodium chloride injection, once daily for waist and abdomen persistent colic because of right ureteral calculi. The patient developed dyspnea, facial swelling, nasal obstruction, runny nose, and laryngeal edema after the first dose of flurbiprofen axetil infusion for about 20 minutes (infusion volume was about 50 ml). Flurbiprofen axetil allergy was considered. Flurbiprofen axetil was stopped immediately and anti-allergy treatments with adrenaline, dexamethasone, budesonide, and promethazine were given, accompanied with symptomatic supportive treatment with oxygen. About 30 minutes later, the patient′s dyspnea relieved and 3 hours later, the facial swelling, nasal obstruction, runny nose, and laryngeal edema disappeared. Then IV infusions of cefuroxime sodium and phloroglucinol were given and the patient′s waist and abdomen pain obviously improved 3 days later.
  • Dai Biao, Wu Xiaoping, Xia Qingrong, Xu Yayun, Zhang Xulai, Cao Yin, Cheng Xialong
    Abstract ( ) PDF ( )
    A 71-year-old male patient received venlafaxine hydrochloride sustained-release capsules 75 mg once daily orally for organic depressive disorder. On day 3 after medication, he developed mild gingival pain. The dose of venlafaxine hydrochloride sustained-release capsules was increased to 150 mg daily because of his condition. Three days later, his gingival pain aggravated significantly. Venlafaxine hydrochloride sustained-release capsules was stopped and oral care was given. On day 4 after the drug withdrawal, his gingival pain disappeared.
  • Zhao Yanyan, Niu Lingling, Li Yuanyuan
    Abstract ( ) PDF ( )
    A 54-year-old female patient received Yuanhu Zhitong dropping pills 30 pills thrice daily for pelvic inflammatory-related abdominal pain. Six months after medication, the patient developed anorexia, nausea, dark brown urine, and skin pruritus.After taking Hugan tablets(护肝片) orally for 2 weeks, the symptoms did not improve. The patient stopped using Yuanhu Zhitong dropping pills by himself. On day 7 of drug withdrawal, the laboratory tests showed alanine aminotransferase(ALT) 679 U/L, aspartate aminotransferase (AST) 698 U/L, total bilirubin (TBil) 66.5 μmol/L, and direct bilirubin (DBil) 51.8 μmol/L. Liver injury induced by Yuanhu Zhitong dropping pills was considered. Hepatoprotection treatments were given. Seven days later, the laboratory tests showed ALT 278 U/L, AST 317 U/L, TBil 150.8 μmol/L, and DBil 115.4 μmol/L. Twenty-five days later, the patient did not complain of discomfort, above symptoms disappeared, and the laboratory tests showed ALT 54 U/L, AST 49 U/L, TBil 44.5 μmol/L, and DBil 39.0 μmol/L. At 4 months of follow-up,  the patient had normal liver function.
  • Zhang Xin, Fang Shengbo, Zhou Na
    Abstract ( ) PDF ( )
    A 27-year-old male patient underwent left maxillary masses excision for periapical cysts in the left maxillary under general anesthesia. During the surgery, a venous access was established from the peripheral vein of the patient′s left lower extremity, and anesthetic drugs (propofol injection, succinylcholine chloride injection, remifentanil hydrochloride for injection, dexmedetomidine hydrochloride injection) were given. On day 2 after surgery, the patient developed topical redness and swelling along the blood vessel on his left lower extremity, which gradually developed into a cord-like redness and swelling, with increased blood vessel stiffness. He was diagnosed with thrombophlebitis of the left great saphenous vein after a ultrasound examination of the blood vessel. Treatments such as subcutaneous injection of enoxaparin sodium, oral administration of extract of horse chestnut seeds, topical mucopolysaccharide polysulfate cream, physiotherapy, and etc. were given. On day 10 after surgery, the redness and swelling on the patient′s left lower extremity disappeared, and the blood vessel was softened. At 2 months of follow-up, ultrasound examination revealed partial recanalization of the left venous trunk (the calf part) of saphenous vein. According to the drug labels and literature reports, it was considered that the patient′s thrombophlebitis might be associated with propofol injection.
  • Wang Xinlu, Li Yueyang, Yan Huiyu, Wang Xiangfeng
    Abstract ( ) PDF ( )
    A 43-year-old female patient was given IV infusions of reduced glutathione for injection (1.2 g,  added in 100 ml of 5% glucose injection), polyenephosphatidylcholine (697.5 mg, added in 250 ml of 5%  glucose injection), and compound glycyrrhizin for injection (120 mg, added in 250 ml of 5% glucose injection) once daily for liver injury. After 20 minutes of the first infusion of compound glycyrrhizin for injection (the injection volume was about 50 ml), the patient developed skin rash, palpitations, dyspnea, drenching sweats, abdominal pain, and dysphoria. Meanwhile her heart rate was 126 beats/min and blood pressure was 85/45 mmHg. In consideration of anaphylactic shock caused by compound glycyrrhizin, the drug was immediately stopped and IV injections of dexamethasone, promethazine hydrochloride, and calcium gluconate were given. Then the patient′s symptoms relieved. Except for polyenephosphatidylcholine, the compound glycyrrhizin for injection and reduced glutathione for injection were discontinued the next day and IV infusion of acetylcysteine (8 g, added in 250 ml of 10% glucose injection) once daily and oral bicyclol tablets 50 mg thrice daily were given. The patient did not developed anaphylaxis again. Seven days later, the patient′s fatigue induced by liver injury obviously improved.
  • Tian Xu, Hou Jiqiu, Li Yanjiao, Zhang Hongmei
    Abstract ( ) PDF ( )
    A 62-year-old female patient received ramipril 2.5 mg orally once daily for hypertension. About 12 hours after the first administration, the patient developed difficulty breathing, multiple skin rashes all over the body (mostly on chest and back, accompanied with itching), conjunctival hyperemia, lip swelling, oral mucosal hyperemia, pharyngeal congestion with pain, and etc. She was diagnosed with angioedema, which was considered to be caused by ramipril. Ramipril was stopped and anti-allergy treatments with adrenaline, promethazine hydrochloride, and dexamethasone were given. One hour later, the patient had improved symptoms and stable vital signs. On day 2 after the anti-allergy treatments, the patient had neither difficulty breathing nor new skin rash, and the anti-allergy drugs were replaced by methylprednisolone, calcium gluconate, and desloratadine cirate disodium. Antihypertensive treatment with levoamlodipine was also given. On day 3 after treatments, the patient′s skin rashes subsided with scars, congestion of the conjunctiva, oral mucosa, and pharynx relieved, and the lip swelling improved. On day 6 after treatments, the patient′s allergic symptoms completely disappeared, and her blood pressure was 122/78 mmHg.
  • Mao Lichao, Zhang Yue, Yan Huiyu, Li Yueyang
    Abstract ( ) PDF ( )
    A 32-year-old woman received IV infusion of doxorubicin hydrochloride liposomes injection 20 mg, added into 5% glucose injection 250 ml, for malignant lymphoma. About 1 minute after the initiation of the IV infusion, the patient developed facial flushing and itchy throat. Two minutes later, the patient developed sudden convulsions, loss of consciousness, binocular gaze, trismus, and urinary incontinence. Anaphylactic shock was diagnosed and the drug was discontinued immediately. Treatments such as intravenous injections of adrenaline hydrochloride injection, dexamethasone sodium phosphate injection, and methylprednisolone sodium succinate for injection, oxygen inhalation, intravenous injections of nikethamide injection, lobeline hydrochloride injection, and norepinephrine bitartrate injection, and cardiopulmonary resuscitation were given successively. However, the patient had been in a deep coma without spontaneous breathing and her blood pressure and urination needed to be maintained by drugs. On day 112 of hospitalization, cerebrovascular color ultrasound showed spectrum changes of brain death. On day 253, the patient was discharged at the request of his family members.
  • Fang Shengbo, Zhang Xiaoying, Li Yueyang, Zhang Wenrui
    Abstract ( ) PDF ( )
    A 12-year-old female pediatric patient received a continuous pumping of somatostatin 3 mg (added to 210 ml of 0.9% sodium chloride injection) by an intravenous detaining needle on the back of her left hand and an IV infusion of pantoprazole sodium for injection 25 mg (added to 100 ml of 0.9% sodium chloride injection) by an intravenous detaining needle on the back of her right hand at the same time for acute pancreatitis. About 5 minutes after the initiation of administration, cyanosis appeared on her both hands, her left hand was cold, and red rashes scattered on her left wrist and upper arm. It was considered as drug-induced anaphylaxis, and the drugs were discontinued immediately. About 40 minutes after drug withdrawal, her above symptoms relieved completely. Pantoprazole for injection was given again that day, and no allergic symptoms were observed. On day 2, a subcutaneous injection of 0.1 g octreotide acetate injection (an analogue of somatostatin) was given. About 10 minutes later, the patient developed headache, nausea, and vomiting, which relieved spontaneously after 30 minutes. It was considered that the anaphylaxis was caused by somatostatin and its analogue octreotide.
  • Nie Xin, Zhang Ping, Cheng Gang, Shi Hong, Li Lin
    Abstract ( ) PDF ( )
    A 70-year-old female patient received chemotherapy regimen of pemetrexed combined with cisplatin for metastatic non-small-cell lung cancer. After 2 cycles of chemotherapy, the tumor partly relieved, but the patient developed grade II leukopenia and serum creatinine elevation. Renal injury was considered to be caused by cisplatin. Therefore, cisplatin was discontinued in the third cycle and pemetrexed monotherapy was given. On day 10 of the chemotherapy, the patient developed fever and laboratory tests revealed pancytopenia, white blood cell count (WBC) 1.1×109/L, neutrophil count 0.54×109/L, platelet count (PLT) 63×109/L, hemoglobin (Hb) 72 g/L, and red blood cell count (RBC) 2.23×1012/L. The patient received symptomatic and supportive treatments such as platelet and erythrocyte suspension infusion, and granulocyte colony stimulating factor subcutaneous injection, but her complete blood count continued to decline, with WBC 0.2×109/L, neutrophil 0.13×109/L, PLT 0×109/L, Hb 59 g/L, and RBC 1.88×1012/L. Ⅳ myelosuppression induced by pemetrexed was diagnosed. Calcium folinate was given for rescue therapy (the first dose was 100 mg/m2, then 50 mg/m2 every 6 hours for 4 days). After 23 days of calcium folinate treatment, the laboratory tests showed WBC 6.8×109/L, neutrophil 3.84×109/L, PLT 169×109/L, Hb 95 g/L, and RBC 2.99×1012/L.
  • Liu Haiyan, Song Yanqing, Ke Wei, Wang Xiangfeng
    Abstract ( ) PDF ( )
    A 74-year-old male patient received an IV infusion of lansoprazole for injection 30 mg twice daily because of gastric cancer accompanied by gastrointestinal hemorrhage. On day 16 of medication, he developed hypourocrinia and laboratory tests showed urea nitrogen 24.5 mmol/L, serum creatinine (Scr) 254 μmol/L, and estimated glomerular filtration rate (eGFR) 23.0 ml/(min·1.73m2). On day 17 of medication, rashes appeared on his back, abdomen, and thigh root. Laboratory tests showed urea nitrogen 30.5 mmol/L, Scr 463 μmol/L, eGFR 11.5 ml/(min·1.73m2), and positive urinary protein (+++). Kidney biopsy showed a large number of lymphocytes infiltration in the renal interstitium. Acute interstitial nephritis was diagnosed, which was considered to be related to lansoprazole for injection. Lansoprazole for injection was stopped and the symptomatic therapy was given. On day 12 of drug withdrawal, the rashes disappeared and laboratory tests showed urea nitrogen 6.9 mmol/L, Scr 127 μmol/L, eGFR 57.6 ml/(min·1.73m2), and negative urinary protein.
  • Liu Limin, Li Hailiang, Pang Lu, Zhu Xu, Zhao Limei
    Abstract ( ) PDF ( )
    Two girls (patient 1, 10 years old; patient 2, 13 years old) received methimazole 10 mg orally twice daily for hyperthyroidism. They developed arthralgia on day 18 and day 20 after medication, respectively. The laboratory tests showed normal rheumatoid factor and negative anti-nuclear antibody. Arthritis syndrome caused by methimazole was considered. Methimazole was stopped in patient 1 immediately. The arthralgia disappeared 3 days after drug withdrawal, and then she was transferred to department of surgery for treatment of primary disease. Patient 2 received gradually reduced dose of methimazole (5 mg twice daily for 3 days, 5 mg daily for 2 days) firstly, but the arthralgia did not improve. Then methimazole was stopped. Four days later, her arthralgia relieved. Patient 2 received methimazole 2.5 mg every morning and 1.25 mg every night again because of recurrence of hyperthyroidism. Four months after remedication, the arthralgia recurred. Methimazole was stopped again and replaced by propylthiouracil 18.75 mg twice daily. Two weeks later, her arthralgia relieved and hyperthyroidism was well controlled. One month later, her arthralgia disappeared.
  • Wang Daimei, Zhao Eryi, Zhong Jingbo, Han Fangxuan, Lyu Xiuping
    Abstract ( ) PDF ( )
    A 22-year-old female patient received methylprednisolone sodium succinate (methyl-prednisolone) for injection(1 000 mg/d for 3 days and gradually reduced to 60 mg/d for maintenance therapy, IV infusion), immunoglobulin (20 g/d, IV infusion), mouse nerve growth factor (20 μg/d, intramuscular injection), vitamin B1 (100 mg/d, intramuscular injection), and mecobalamin(1 mg/d, IV injection) for multiple sclerosis. Twelve days later, mouse nerve growth factor was temporarily discontinued and 7 days later, the drug was given again. On day 2 of retreatment, the patient developed conjunctival congestion. On day 3 of retreatment, red spots appeared on her chest, back, abdomen, and forearms. Then the rashes gradually increased, linked into pieces, and spread all over the body. Rashes partly formed blisters, blisters ulcerated, and epidermis exfoliated. It was considered that mouse nerve growth factor induced the toxic epidermal necrolysis. Then the drug was discontinued, the dose of methylprednisolone was increased to 500 mg/d, and at the same time, immunoglobulin, desloratadine, and fexofenadine were given. Twenty days later, the rashes subsided and pigmentation remained.
  • Yao Fei
    Abstract ( ) PDF ( )
    A 72-year-old male patient received endocrine therapy with oral bicalutamide (50 mg, once daily) and subcutaneous injection of leuprorelin acetate microspheres sustained release for injection (3.75 mg, once per 4 weeks) as well as treatment for bone pain with IV infusion of zoledronic acid injection (4 mg once per 4 weeks, added into 100 ml of 0.9% sodium chloride injection) for prostate cancer with multiple bone metastases. After more than 9 months of treatments, the patient developed dyspnea and then fever. He was diagnosed as having pneumonia through CT examination of the lungs. The patient′s symptoms did not improve after anti-infective treatments. The respiratory physician considered the patient to have interstitial pneumonia caused by bicalutamide. The drug was discontinued, and methylprednisolone (the initial dose was 240 mg, which was gradually reduced after the symptoms improved) was given. The patient′s symptoms improved, and the chest X-ray examination showed that the lung inflammation was reduced.
  • Wang Chunhui, Wang Weiguang, Li Xiaoyu, Lyu Qianzhou, Liu Peng
    Abstract ( ) PDF ( )
    A 53-year-old male patient with follicular lymphoma received R-GDP chemotherapy regimen (rituximab+gemcitabine+dexamethasone; the treatment course was 21 days), which was terminated for drug-induced renal injury occurring on day 5 of the treatment.  The patient developed scrotal edema 14 days after the initial treatment and lenalidomide 10 mg was given orally once daily 16 days after the initial treatment. On day 5 of lenalidomide administration, the patient was treated with R-FC chemotherapy regimen (rituximab+fludarabine+cyclophosphamide; the treatment course was 28 days). On day 17, the scrotal edema relieved, but agranulocytosis[white blood count (WBC) 1.8×109/L, neutrophil ratio 0.06] occurred. Lenalidomide was considered to be the cause and was discontinued. On day 9 after lenalidomide withdrawal, the patient′s WBC was 6.8 ×109/L and neutrophil ratio was 0.48. Lenalidomide was re-given orally in consideration of the need for cancer treatment. On day 4 of lenalidomide re-administration, the patient developed low fever, left lower extremity pain, and increased bilateral inguinal lymph node mass. On day 7 to day 9, the pain and muscle tone of his left lower extremity increased and, in consideration of the tumor flare reaction caused by lenalidomide, morphine and dexamethasone were given, after which the pain decreased and the body temperature returned to normal. On day 15, his left lower extremity pain increased again and then improved after fentanyl and methylprednisolone treatment. On day 18, the patient re-examination showed WBC 0.5×107/L and neutrophil ratio 0.24. Lenalidomide therapy was terminated. On day 26, the patient′s WBC was 4.2×109/L, neutrophil ratio was 0.85, and he was transferred to other hospitals.